Journal
LUPUS
Volume 21, Issue 11, Pages 1178-1182Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/0961203312450084
Keywords
systemic lupus erythematosus; lipoprotein; antimalarial; hydroxychloroquine; dyslipidemia; therapy
Categories
Funding
- Programa para la Investigacion Biomedica PROINBIO, Facultad de Medicina, Universidad de la Republica
- Comision Sectorial de Investigacion Cientifica (CSIC), Universidad de la Republica
- Agencia Nacional de Investigacion e Innovacion (ANII), Uruguay
- Programa para la Investigacion Biomedica, PROINBIO, Facultad de Medicina, Universidad de la Republica
- Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [303165/2008-1]
- Federico Foundation
Ask authors/readers for more resources
The influence of antimalarials on lipids in systemic lupus erythematosus (SLE) has been identified in several studies but not in many prospective cohorts. The aim of this study was to longitudinally determine the effect of antimalarials on the lipoprotein profile in SLE. Patients and methods: Fasting total cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDL) and low-density lipoprotein cholesterol (LDL) plasma levels were determined at entry and after 3 months of hydroxychloroquine (HCQ) treatment in a longitudinal evaluation of 24 patients with SLE. Results: a significant decrease in TC (198 +/- 33.7 vs. 183 +/- 30.3 mg/dl, p = 0.023) and LDL levels (117 +/- 31.3 vs. 101 +/- 26.2 mg/dl, p = 0.023) were detected after the 3 months of HCQ therapy. The reduction of 7.6% in TC (p = 0.055) and 13.7% in LDL levels (p = 0.036) determined a significant decrease in the frequency of dyslipidemia (26% vs. 12.5%, p = 0.013) after HCQ therapy. Conclusion: This longitudinal study demonstrated the beneficial effect of antimalarials on lipids in SLE since this therapy induced a reduction of atherogenic lipoproteins. Lupus (2012) 21, 1178-1182.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available